论文部分内容阅读
目的:探讨核内原癌基因(nuclear oncogene,MYC)、B细胞淋巴瘤/白血病-2基因(B cell lymphoma/leukemia 2 gene,Bcl-2)、细胞周期蛋白D1(Ccnd1)和细胞角蛋白19(cytokeratin 19,CK19)基因表达水平在乳腺癌诊断和治疗监测中的应用。方法:建立荧光定量聚合酶链反应(FQ-PCR)法,并以GAPDH为内对照测定34名健康女性体检者、55例良性乳腺疾病患者和91例乳腺癌患者外周血中MYC,Ccnd1,Bcl-2和CK19的表达量。结果:MYC,Ccnd1,Bcl-2和CK19表达水平与GAPDH的比值在乳腺癌组显著高于健康女性体检者和良性乳腺疾病患者(P<0.05)。它们在正常对照组和良性乳腺疾病组间差异无统计学意义(P>0.05)。四组GAPDH差异无统计学意义(P>0.05)。MYC,Ccnd1,Bcl-2与CK19联合检测的灵敏度高于单个基因的检测。结论:FQ-PCR技术可以快速定量检测MYC,Ccnd1,Bcl-2和CK19 mRNA,四者联合检测可有效提高对乳腺癌诊断的灵敏度。
Objective: To investigate the expression of nuclear oncogene (MYC), B cell lymphoma / leukemia 2 gene (Bcl-2), cyclin D1 (Ccnd1) and cytokeratin 19 Cytokeratin 19, CK19) gene expression in the diagnosis and treatment of breast cancer. Methods: FQ-PCR was used to detect the expression of MYC, Ccnd1, Bcl-2 in peripheral blood of 34 healthy women, 55 benign breast disease patients and 91 breast cancer patients by GAPDH as internal control. -2 and CK19 expression levels. Results: The ratios of MYC, Ccnd1, Bcl-2 and CK19 to GAPDH in breast cancer patients were significantly higher than those in healthy women and benign breast disease patients (P <0.05). There was no significant difference between normal control group and benign breast disease group (P> 0.05). Four groups of GAPDH difference was not statistically significant (P> 0.05). The sensitivity of the combined detection of MYC, Ccnd1, Bcl-2 and CK19 was higher than that of single gene. Conclusion: FQ-PCR can rapidly and quantitatively detect MYC, Ccnd1, Bcl-2 and CK19 mRNA. The combination of four detection methods can effectively improve the sensitivity of breast cancer diagnosis.